Frequent hyperphosphorylation of AS160 in breast cancer

Cancer Biology and Therapy

Volumn 10, Issue 4, 2010, Pages 362-367

  Jiang, Xiao Hua ^a,b   Sun, Jian Wen ^b   Xu, Ming ^a   Jiang, Xiao Fei ^a   Liu, Chun Fang ^a   Lu, Yuan ^a  

^a FUDAN UNIVERSITY   (China)

^b No 85 Hospital of PLA   (China)

Author keywords

Akt substrate of 160 kDa (AS160); Breast cancer; Immunohistochemistry

Indexed keywords

AKT SUBSTRATE OF 160 KDA; GLUCOSE TRANSPORTER; KI 67 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER SIZE; CELL PROLIFERATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PROTEIN PHOSPHORYLATION; SCORING SYSTEM; WESTERN BLOTTING;

AGE FACTORS; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; BREAST NEOPLASMS; FEMALE; GLUCOSE; GTPASE-ACTIVATING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR MARKERS, BIOLOGICAL;

EID: 77957141714     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.4.12426     Document Type: Article

References (30)

1. Botha JL, Bray F, Sankila R, Parkin DM. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 2003; 39:1718-29.
2. Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol 2002; 3:267-77. (Pubitemid 34619262)
3. Watson RT, Kanzaki M, Pessin JE. Regulated membrane trafficking of the insulin-responsive glucose transporter 4 in adipocytes. Endocr Rev 2004; 25:177-204.
4. Geraghty KM, Chen S, Harthill JE, Ibrahim AF, Toth R, Morrice NA, et al. Regulation of multisite phosphorylation and 14-3-3 binding of AS160 in response to IGF-1, EGF, PMA and AICAR. Biochem J 2007; 407:231-41.
5. Kane S, Sano H, Liu SCH, Asara JM, Lane WS, Garner CC, et al. A method to identify serine kinase substrates. Akt phosphorylates a novel adipocyte protein with a Rab GTPase-activating protein (GAP) domain. J Biol Chem 2002; 277:22115-8.
6. Thong FSL, Bilan PJ, Klip A. The Rab GTPaseactivating protein AS160 integrates Akt, protein kinase C and AMP-activated protein kinase signals regulating GLUT4 traffic. Diabetes 2007; 56:414-23. (Pubitemid 46263089)
7. Yuasa T, Uchiyama K, Ogura Y, Kimura M, Teshigawara K, Hosaka T, et al. The Rab GTPase-activating protein AS160 as a common regulator of insulin- and Galphaq-mediated intracellular GLUT4 vesicle distribution. Endocr J 2009; 56:345-59.
8. Eguez L, Lee A, Chavez JA, Miinea CP, Kane S, Lienhard GE, et al. Full intracellular retention of GLUT4 requires AS160 Rab GTPase activating protein. Cell Metab 2005; 2:263-72.
9. Zeigerer A, McBrayer MK, McGraw TE. Insulin stimulation of GLUT4 exocytosis, but not its inhibition of endocytosis, is dependent on RabGAP AS160. Mol Biol Cell 2004; 15:4406-15.
10. Sano H, Kane S, Sano E, Mîinea CP, Asara JM, Lane WS, et al. Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem 2003; 278:14599-602.
11. Larance M, Ramm G, Stöckli J, van Dam EM, Winata S, Wasinger V, et al. Characterization of the role of the Rab GTPase-activating protein AS160 in insulin-regulated GLUT4 trafficking. J Biol Chem 2005; 280:37803-13.
12. Dugani CB, Randhawa VK, Cheng AWP, Patel N, Klip A. Selective regulation of the perinuclear distribution of glucose transporter 4 (GLUT4) by insulin signals in muscle cells. Eur J Cell Biol 2008; 87:337-51.
13. Karlsson HKR, Zierath JR, Kane S, Krook A, Lienhard GE, Wallberg-Henriksson H. Insulin-stimulated phosphorylation of the Akt substrate AS160 is impaired in skeletal muscle of type 2 diabetic subjects. Diabetes 2005; 54:1692-7. (Pubitemid 40770759)
14. Ngo S, Barry JB, Nisbet JC, Prins JB, Whitehead JP. Reduced phosphorylation of AS160 contributes to glucocorticoid-mediated inhibition of glucose uptake in human and murine adipocytes. Mol Cell Endocrinol 2009; 302:33-40.
15. Moadel RM, Weldon RH, Katz EB, Lu P, Mani J, Stahl M, et al. Positherapy: targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose. Cancer Res 2005; 65:698-702.
16. Tokunaga E, Kataoka A, Kimura Y, Oki E, Mashino K, Nishida K, et al. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer 2006; 42:629-35.
17. Vestey SB, Sen C, Calder CJ, Perks CM, Pignatelli M, Winters ZE. Activated Akt expression in breast cancer: correlation with p53, Hdm2 and patient outcome. Eur J Cancer 2005; 41:1017-25. (Pubitemid 40602853)
18. Salh B, Marotta A, Wagey R, Sayed M, Pelech S. Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer. Int J Cancer 2002; 98:148-54.
19. Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S, et al. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 2006; 13:137-44.
20. Sahoo S, Brickley DR, Kocherginsky M, Conzen SD. Coordinate expression of the PI3-kinase downstream effectors serum and glucocorticoid-induced kinase (SGK-1) and Akt-1 in human breast cancer. Eur J Cancer 2005; 41:2754-9.
21. Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res 2005; 65:1027-34. (Pubitemid 40216465)
22. Ramm G, Larance M, Guilhaus M, James DE. A role for 14-3-3 in insulin-stimulated GLUT4 translocation through its interaction with the RabGAP AS160. J Biol Chem 2006; 281:29174-80.
23. Thor AD, Liu S, Moore DH, Edgerton SM. Comparison of mitotic index, in vitro bromodeoxyuridine labeling and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 1999; 17:470-7.
24. Younes M, Brown RW, Mody DR, Fernandez L, Laucirica R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res 1995; 15:2895-8. (Pubitemid 26095119)
25. Rastogi S, Banerjee S, Chellappan S, Simon GR. Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Lett 2007; 257:244-51.
26. Smith TA, Titley JC. Uptake of glucose analogues by colonic tumour cells during growth and after treatment with hydroxyurea. Cancer Lett 1999; 141:85-91.
27. Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001; 42:9-16.
28. Buck A, Schirrmeister H, Kühn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002; 29:1317-23.
29. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36:1766-74.
30. Jalava P, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P, Collan Y. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 2006; 48:674-82.